Latest news from BIA

View all news
BIA blog
12 May 23
BIA Blog

UK biotech shows progress on diversity - and has more to do

Industry survey on Diversity, Equity and Inclusion (DEI) can guide efforts to expand the talent pool and investment in UK biotech, says Alina O’Keeffe, Head of Marketing and Membership Communications at the BIA.

09 May 23
BIA Blog

CEO Update - 9 May 2023

It was heartening last week to see positive results from Lilly's trial of donanemab for Alzheimer’s disease. It is an important step and, although there is a long way to go before products like these become routine in clinical practice in the UK, it is great to see positive news. An experimental Alzheimer's drug slowed cognitive decline by 35% in a late-stage trial with 1,182 people, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Read on for VPAS, local elections, FCA reforms and a new approach to importing into Great Britain.

09 May 23
BIA Blog

Prioritising patient access - The life sciences industry has entered a golden age of innovation

Next-generation sequencing and many other tools provide tremendous new insights into human biology. Emerging techniques, such as CRISPR technology and cell and gene therapies are providing new opportunities to treat and possibly even cure some of the most intractable diseases.

04 May 23
BIA Blog

New Act opens doors for modern biotechnology in England

The Genetic Technologies (Precision Breeding) Act was passed into law in England in March 2023 to enable the development and marketing of gene-edited crops and animals in England, allowing us to grow more resilient crops and breed animals that are more resistant to harmful diseases and put those to market.

See More

 

Member News
12 May 23
Member News

Exploristics launches the KerusCloud Spring 2023 Release

Exploristics is delighted to launch the Spring 2023 release of its transformative clinical trial simulation software KerusCloud. This innovative platform is revolutionising how clinical trials are being designed.

12 May 23
Member News

Overcoming six challenges in commercialising cell and gene therapies

Pooja Bakhai and Jessica Lee at Syneos Health Consulting, Inc explore ways to overcome six challenges in commercialising cell and gene therapies.

12 May 23
Member News

PIR International BioLeader Interviews Damian Marron, board director Cantargia AB, Targovax ASA, CytoSeek, Imophoron, Resolys Bio

For the latest interview in their BioLeaders series, PIR International spoke with experienced biotech board Chair and NED Damian Marron.

12 May 23
Member News

Redx's discovery of pirtobrutinib recognised with unveiling of commemorative plaque

Redx, the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease confirms that a commemorative plaque has been unveiled by Bruntwood SciTech at their Alderley Park campus, where Redx is headquartered, in recognition of the team's discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's Jaypirca™.

See More

 

Latest resources

Here's a selection of featured BIA publications. See Resources Hub  

02 May 23
News Report

Influencing and shaping our sector | BIA update: January - April 2023

Advocating for the life science and biotech sector: report on how BIA is influencing change with government stakeholders.

02 May 23
Policy Briefing

Guide to the Government for BIA members - May 2023

BIA member's guide to the government: This document provides an extensive guide to the Government for BIA Members, with focus on recent government changes and newly created Department for Science, Innovation and Technology

24 Apr 23
Guidance document

USIT Guide

05 Apr 23
Research Publications

Rare insights: examining the social values of treating rare diseases

 

Press Releases
24 Apr 23
Press Release

Venture deals continue to flow for UK biotech under dark clouds

The first quarter of 2023 has seen deal flow continue for the UK’s innovative life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. As global macro-economic headwinds, suppressed public markets and political uncertainty weighed on investor confidence, venture investment remained steady, with private UK biotechs securing £258 million across 20 deals, with an average deal size of £13 million.

05 Apr 23
Press Release

BIA calls on NICE to refresh evidence informing how rare disease medicines are evaluated and paid for

The UK BioIndustry Association has today published research suggesting the UK’s medicines evaluation body is basing its methods and processes for evaluating medicines for rare diseases on outdated evidence. Rare insights: examining the social values of treating rare diseases presents the findings of primary research into public opinion on how treatments for rare diseases should be evaluated and funded within the NHS.

27 Mar 23
Press Release

BIA launched first of its kind Diversity and Inclusion report for UK biotech and life sciences

The importance of building a thriving, diverse workplace is a widely recognised priority across all industries. The first of its kind sector data analysis by the BioIndustry Association (BIA) demonstrates strong inclusivity and an overall level of diversity in talent working within the UK innovative life sciences and biotech sector. The new state of the nation report, Diversity and Inclusion in UK Biotech, also reveals significant diversity gaps across disciplines, management levels and demographic traits which require action at both a company and sector level.

15 Mar 23
Press Release

Chancellor gives boost to medical innovation and life sciences industry in Spring Budget

The UK’s Chancellor, Jeremy Hunt, has announced a special higher R&D tax relief rate for the UK’s most innovative businesses in his Spring Budget today (15 March). The UK’s trade association for innovative life sciences and biotech, the UK BioIndustry Association (BIA), has warmly welcomed the announcement.

See More

 

The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation.

Explore opportunities to influence, connect and save with the BIA.

Influence

Influence

 Connect

Connect

 Save

Save 

policymakers, ensuring your voice is heard on the matters that are critical to the success of your organisation

with the UK ecosystem
through industry-leading events, expert committees and overseas missions

money with the BIA Business Solutions purchasing programme, helping you start, grow and deliver world-changing innovation
 
Learn more about BIA Membership
 
 
See who's in our Membership Directory